Jessica Fye
Stock Analyst at J.P. Morgan
(4.54)
# 996
Out of 4,517 analysts
570
Total ratings
55.1%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Buy | $72 | $54.20 | +32.84% | 31 | Jul 14, 2026 | |
| AKTS Aktis Oncology | Rated: Buy | $30 → $33 | $25.50 | +29.41% | 2 | Jul 14, 2026 | |
| ALKS Alkermes | Maintained: Hold | $35 → $60 | $52.24 | +14.85% | 14 | Jul 13, 2026 | |
| BCRX BioCryst Pharmaceuticals | Initiated Coverage: Hold | $13 → $12 | $9.19 | +30.58% | 19 | Jul 13, 2026 | |
| NVCR NovoCure | Maintained: Hold | $23 → $17 | $16.08 | +5.72% | 15 | Jul 13, 2026 | |
| DNLI Denali Therapeutics | Initiated Coverage: Buy | $26 → $29 | $23.61 | +22.83% | 17 | Jul 13, 2026 | |
| LEGN Legend Biotech | Initiated Coverage: Hold | $76 → $35 | $22.50 | +55.56% | 13 | Jul 13, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | n/a | $270.87 | - | 25 | Jul 9, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $115 → $125 | $119.10 | +4.95% | 13 | Jul 2, 2026 | |
| MRNA Moderna | Maintained: Sell | n/a | $62.72 | - | 22 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $265.56 | - | 48 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $180 → $179 | $108.99 | +64.24% | 26 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $247.70 | - | 32 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $312.21 | - | 12 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $30 | $68.50 | -56.20% | 31 | Nov 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $25 | $29.33 | -14.75% | 17 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $59.73 | - | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $63 → $65 | $77.75 | -16.40% | 19 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $121 → $120 | $91.91 | +30.56% | 29 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $117.16 | - | 23 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $10 | $14.18 | -29.50% | 10 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $52.66 | - | 3 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $517 → $530 | $484.31 | +9.43% | 21 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 → $52 | $83.90 | -38.02% | 15 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $450 | $536.67 | -16.15% | 32 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $61.87 | n/a | 3 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $34.96 | n/a | 14 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | n/a | $7.59 | n/a | 13 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 → $14 | $24.41 | n/a | 4 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 → $5 | $2.32 | n/a | 12 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $19 | $3.16 | n/a | 4 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $0.67 | n/a | 3 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $7 | $102.82 | n/a | 3 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $94 → $66 | $150.40 | n/a | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $8.25 | n/a | 3 | Mar 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $95 | $13.80 | n/a | 4 | Feb 8, 2018 |
Ionis Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $72
Current: $54.20
Upside: +32.84%
Aktis Oncology
Jul 14, 2026
Rated: Buy
Price Target: $30 → $33
Current: $25.50
Upside: +29.41%
Alkermes
Jul 13, 2026
Maintained: Hold
Price Target: $35 → $60
Current: $52.24
Upside: +14.85%
BioCryst Pharmaceuticals
Jul 13, 2026
Initiated Coverage: Hold
Price Target: $13 → $12
Current: $9.19
Upside: +30.58%
NovoCure
Jul 13, 2026
Maintained: Hold
Price Target: $23 → $17
Current: $16.08
Upside: +5.72%
Denali Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $26 → $29
Current: $23.61
Upside: +22.83%
Legend Biotech
Jul 13, 2026
Initiated Coverage: Hold
Price Target: $76 → $35
Current: $22.50
Upside: +55.56%
Alnylam Pharmaceuticals
Jul 9, 2026
Maintained: Buy
Price Target: n/a
Current: $270.87
Upside: -
Mirum Pharmaceuticals
Jul 2, 2026
Maintained: Buy
Price Target: $115 → $125
Current: $119.10
Upside: +4.95%
Moderna
Jun 18, 2026
Maintained: Sell
Price Target: n/a
Current: $62.72
Upside: -
Jun 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $265.56
Upside: -
Jun 8, 2026
Rated: Buy
Price Target: $180 → $179
Current: $108.99
Upside: +64.24%
Jun 2, 2026
Maintained: Buy
Price Target: n/a
Current: $247.70
Upside: -
Jun 2, 2026
Maintained: Buy
Price Target: n/a
Current: $312.21
Upside: -
Nov 9, 2025
Maintained: Sell
Price Target: $30
Current: $68.50
Upside: -56.20%
Nov 3, 2025
Maintained: Hold
Price Target: $15 → $25
Current: $29.33
Upside: -14.75%
Oct 27, 2025
Maintained: Buy
Price Target: n/a
Current: $59.73
Upside: -
Oct 27, 2025
Maintained: Hold
Price Target: $63 → $65
Current: $77.75
Upside: -16.40%
Oct 23, 2025
Maintained: Hold
Price Target: $121 → $120
Current: $91.91
Upside: +30.56%
Oct 20, 2025
Maintained: Hold
Price Target: n/a
Current: $117.16
Upside: -
Oct 17, 2025
Maintained: Sell
Price Target: $10
Current: $14.18
Upside: -29.50%
Oct 13, 2025
Maintained: Buy
Price Target: n/a
Current: $52.66
Upside: -
Oct 8, 2025
Maintained: Buy
Price Target: $517 → $530
Current: $484.31
Upside: +9.43%
Sep 24, 2025
Reiterated: Buy
Price Target: $53 → $52
Current: $83.90
Upside: -38.02%
Sep 9, 2025
Maintained: Buy
Price Target: $450
Current: $536.67
Upside: -16.15%
Jun 16, 2025
Maintained: Buy
Price Target: n/a
Current: $61.87
Upside: n/a
Apr 11, 2025
Maintained: Buy
Price Target: $50
Current: $34.96
Upside: n/a
Nov 20, 2023
Initiated Coverage: Sell
Price Target: n/a
Current: $7.59
Upside: n/a
Jun 7, 2022
Maintained: Hold
Price Target: $18 → $14
Current: $24.41
Upside: n/a
Apr 7, 2022
Maintained: Hold
Price Target: $7 → $5
Current: $2.32
Upside: n/a
Mar 14, 2022
Maintained: Buy
Price Target: $20 → $19
Current: $3.16
Upside: n/a
Aug 20, 2021
Downgraded: Sell
Price Target: n/a
Current: $0.67
Upside: n/a
Aug 3, 2021
Downgraded: Hold
Price Target: $13 → $7
Current: $102.82
Upside: n/a
Apr 6, 2020
Maintained: Hold
Price Target: $94 → $66
Current: $150.40
Upside: n/a
Mar 19, 2018
Downgraded: Sell
Price Target: n/a
Current: $8.25
Upside: n/a
Feb 8, 2018
Downgraded: Hold
Price Target: $32 → $95
Current: $13.80
Upside: n/a